SLS
Income statement / Annual
Last year (2024), SELLAS Life Sciences Group, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, SELLAS Life Sciences Group, Inc.'s net income was -$30.88 M.
See SELLAS Life Sciences Group, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$1.00 M |
$7.60 M |
$1.90 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$100.00 K
|
$200.00 K
|
$377.00 K
|
$0.00
|
$0.00
|
$0.00
|
$3.00 K
|
$355.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$900.00 K
|
$7.40 M
|
$1.90 M
|
$0.00
|
$0.00
|
$0.00
|
-$3.00 K
|
-$355.00 K
|
| Gross Profit Ratio |
0
|
0
|
0.9
|
0.97
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$19.10 M
|
$24.01 M
|
$30.27 M
|
$21.37 M
|
$9.28 M
|
$7.29 M
|
$18.32 M
|
$6.07 M
|
$19.86 M
|
$23.61 M
|
| General & Administrative Expenses |
$12.42 M
|
$13.86 M
|
$12.58 M
|
$11.32 M
|
$9.60 M
|
$9.92 M
|
$12.77 M
|
$15.09 M
|
$12.01 M
|
$10.61 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.42 M
|
$13.86 M
|
$12.58 M
|
$11.32 M
|
$9.60 M
|
$9.92 M
|
$12.77 M
|
$15.09 M
|
$12.01 M
|
$10.25 M
|
| Other Expenses |
$0.00
|
$0.00
|
$10.00 M
|
$5.70 M
|
$0.00
|
$0.00
|
-$3.03 M
|
$0.00
|
$0.00
|
$509.00 K
|
| Operating Expenses |
$31.51 M
|
$37.87 M
|
$42.85 M
|
$32.69 M
|
$18.88 M
|
$17.21 M
|
$31.59 M
|
$21.16 M
|
$31.87 M
|
$33.87 M
|
| Cost And Expenses |
$0.00
|
$37.87 M
|
$42.95 M
|
$32.89 M
|
$18.88 M
|
$17.21 M
|
$31.09 M
|
$21.16 M
|
$31.87 M
|
$34.22 M
|
| Interest Income |
$632.00 K
|
$525.00 K
|
$317.00 K
|
$6.00 K
|
$26.00 K
|
$118.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$118.00 K
|
$266.00 K
|
$462.00 K
|
$3.51 M
|
$760.00 K
|
| Depreciation & Amortization |
$31.51 M
|
$37.87 M
|
$457.00 K
|
$1.27 M
|
$282.00 K
|
$17.21 M
|
$22.04 M
|
$3.00 K
|
$3.00 K
|
$355.00 K
|
| EBITDA |
-$30.88 M |
$529.00 K |
-$31.95 M |
-$19.59 M |
-$16.40 M |
$668.00 K |
$0.00 |
-$23.04 M |
-$15.99 M |
-$37.48 M |
| EBITDA Ratio |
0
|
0
|
-31.95
|
-2.58
|
-8.63
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
-41.95
|
-3.33
|
-8.94
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$632.00 K
|
$529.00 K
|
$649.00 K
|
$4.36 M
|
$208.00 K
|
$668.00 K
|
$2.54 M
|
-$7.79 M
|
$5.13 M
|
-$4.37 M
|
| Income Before Tax |
-$30.88 M
|
-$37.34 M
|
-$41.30 M
|
-$20.94 M
|
-$16.77 M
|
-$19.37 M
|
-$29.05 M
|
-$23.50 M
|
-$17.68 M
|
-$38.59 M
|
| Income Before Tax Ratio |
0
|
0
|
-41.3
|
-2.75
|
-8.83
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$649.00 K
|
-$237.00 K
|
-$17.00 K
|
-$81.00 K
|
-$1.38 M
|
$253.00 K
|
$243.00 K
|
$365.00 K
|
| Net Income |
-$30.88 M
|
-$37.34 M
|
-$41.30 M
|
-$20.70 M
|
-$16.76 M
|
-$19.29 M
|
-$27.67 M
|
-$23.75 M
|
-$23.55 M
|
-$63.90 M
|
| Net Income Ratio |
0
|
0
|
-41.3
|
-2.72
|
-8.82
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.0505 |
-0.15 |
-2.13 |
-1.34 |
-2.11 |
-0.84 |
-11.76 |
-56.39 |
-394.12 |
-1372.03 |
| EPS Diluted |
-0.0505 |
-0.15 |
-2.13 |
-1.34 |
-2.11 |
-0.84 |
-11.76 |
-56.39 |
-394.12 |
-1372.02 |
| Weighted Average Shares Out |
$612.02 M
|
$249.99 M
|
$19.40 M
|
$15.48 M
|
$7.98 M
|
$23.03 M
|
$2.35 M
|
$45.00 K
|
$59.75 K
|
$46.57 K
|
| Weighted Average Shares Out Diluted |
$612.02 M
|
$249.99 M
|
$19.40 M
|
$15.48 M
|
$7.98 M
|
$23.03 M
|
$2.35 M
|
$46.81 K
|
$59.75 K
|
$46.58 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
